Search

everythinglearnresearchcommunity

for

Search:↓

Men with baldness at the front and top of their head at age 45 may have a higher risk of aggressive prostate cancer.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

Physical activity, height, and smoking affect prostate cancer risk.

New treatments are making advanced prostate cancer management more complex but also more hopeful.

Black ethnicity, prior PSA tests, enlarged prostate, and family history increase prostate cancer risk; Asian ethnicity, obesity, smoking, diabetes, and less sexual activity or no children decrease risk.

Green-synthesized nanoparticles can effectively target cancer cells, reducing side effects and improving treatment.

Flutamide rarely causes liver toxicity in prostate cancer patients.

Plant-based compounds might be effective, low-side-effect treatments for prostate cancer by blocking a specific enzyme.

CT scans can find serious prostate cancer even when PSA levels are low.

Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.

Prostate cancer can progress even with low testosterone due to internal hormone production in the tumor.

Androgen deprivation therapy doesn't lower the risk of death from COVID-19 in prostate cancer patients.

People with certain types of alopecia have a slightly higher risk of cancer, especially thyroid, bladder, and prostate cancers.

Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.

Male pattern baldness does not cause an increased risk of prostate cancer.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

Finasteride treats hair loss and reduces prostate cancer risk.

Stem cell niches are crucial for regulating stem cell behavior and tissue health, and their decline can impact aging and cancer.

The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.

Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.

5α‐reductase isozymes are crucial for prostate development and health, and targeting them can help prevent and treat prostate issues.

Using finasteride with TIP extends time off period for prostate cancer patients.

Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.

A new mutation linked to partial Androgen Insensitivity Syndrome and prostate cancer was found in a patient unhappy with their female gender assignment.

The conclusion is that individualized treatment and proper medication use are crucial in men's health, with specific recommendations for ED, BPH, and prostate cancer management.

Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.

Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.

Different types of stem cells exist within individual skin layers, and they can adapt to damage, transplantation, or tumor growth. These cells are regulated by their environment and genetic factors. Tumor growth is driven by expanding, genetically altered cells, not long-lived mutant stem cells. There's evidence of cancer stem cells in skin tumors. Other cells, bacteria, and genetic factors help maintain balance and contribute to disease progression. A method for growing mini organs from single cells has been developed.

Disrupting Stat3 in hair follicle stem cells greatly reduces skin tumor formation.